Note from 340B Report Publisher and CEO Ted Slafsky: I look forward to moderating a panel on the latest 340B developments, President Trump’s drug pricing executive orders, as well as the upcoming elections this Tuesday, Sept. 29 at 12:00
…Category: Pharma Industry
HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy
The top lawyer at the U.S. Health and Human Services (HHS) department told drug manufacturer Eli Lilly and Co. in a letter dated Sept. 21 and made
…Breaking News
BREAKING: 22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions
22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions
Twenty-two Democratic U.S. senators asked Pharmaceutical Research and Manufacturers of America (PhRMA) today to inform them by no later than Sept. 29 “regarding steps being taken by
…Note from Publisher and CEO Ted Slafsky: I encourage you to read today’s sponsored content article from 340B Report sponsor Trellis Rx about a Sept. 22 panel discussion on recent manufacturer actions in the contract pharmacy space as well as mitigation
…Breaking News
BREAKING: More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately
More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately
More than half of the U.S. House today told U.S. Health and Human Services (HHS) Secretary Alex Azar “it is imperative that immediate action
…Note from the Publisher and CEO Ted Slafsky: I want to acknowledge this date, Sept. 11, and its solemn importance to our country. We honor those who were lost 19 years ago today and continue to cherish the great work of
…Health Centers Are Preparing to Sue Over Drug Makers’ 340B Actions
The National Association of Community Health Centers (NACHC) “is preparing legal action” in response to drug manufacturers’ recent unilateral moves to stop providing reduced 340B pricing on their products
…Breaking News
BREAKING: House Democratic Committee Chairs Say Drug Companies’ Actions Could Put 340B on “Treacherous Path”
House Democratic Committee Chairs Say Drug Companies’ Actions Could Put 340B on “Treacherous Path”
Letting drug manufacturers “pick and choose” which 340B program requirements they will comply with “could set us on a treacherous path where program participants might disregard
…HRSA is Investigating Whether Manufacturer Policies to Restrict 340B Pricing at Contract Pharmacies Violates Statute
In a major development, the Health Resources and Services Administration (HRSA) has told 340B Report that it is investigating whether recent manufacturer policies to restrict
…